作者: Deepa S. Subramaniam , Claudine Isaacs
DOI: 10.1007/S11864-005-0022-1
关键词:
摘要: In order to make optimal treatment recommendations for patients with early-stage breast cancer, it is essential accurately determine the patient’s underlying risk of disease recurrence and choose a therapy which individual most likely respond. Lymph node status, tumor size, histopathologic features including type grade, hormone receptor status are well-accepted prognostic factors related cancer. addition, very strong predictor response hormonal therapy. However, our currently accepted predictive fall short there critical need more identify those require or benefit from particular therapies. Attention has therefore focused on determination novel factors. The promising new factor level urokinase plasminogen activator its inhibitor inhibitor. Other putative include proliferative rate, presence lymphatic vascular invasion, human epidermal growth 2 (HER-2/neu erbB-2) positivity, micrometastases in lymph nodes bone marrow, gene expression profile by microarray analysis, RNA-based methodology. Data regarding potential constantly emerging. These studies frequently challenging interpret as they often retrospective, based relatively small numbers patients, mix treated untreated women, do not control other known Therefore, data must be interpreted caution.